Aleš Ryška
Impact in
- Oncology top 1%
- Ear and Head Tumors
- Cancer Immunotherapy and Biomarkers
- Oral Surgery top 1%
- Oral and Maxillofacial Pathology
Papers in
- Oncology 77
- Cancer Immunotherapy and Biomarkers 15
-
- Cancer Genomics and Diagnostics 21
- Breast Cancer Treatment Studies 11
Aleš Ryška
178 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 1.8k
- Oral Surgery 384
- Otorhinolaryngology 197
- Cancer Research 628
- Dermatology 288
Countries citing papers authored by Aleš Ryška
This map shows the geographic impact of Aleš Ryška's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleš Ryška with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleš Ryška more than expected).
Fields of papers citing papers by Aleš Ryška
This network shows the impact of papers produced by Aleš Ryška. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleš Ryška. The network helps show where Aleš Ryška may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Aleš Ryška, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 10 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 23 | |
| 5 | 2022 | 3 | |
| 6 | Review of tumor infiltrating lymphocytes assessment in breast cancer in routine diagnostic practice. | 2021 | 0 |
| 7 | 2020 | 7 | |
| 8 | 2019 | 16 | |
| 9 | 2019 | 6 | |
| 10 | 2018 | 0 | |
| 11 | 2018 | 11 | |
| 12 | [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations]. | 2018 | 1 |
| 13 | 2016 | 3 | |
| 14 | [Molecular diagnostics of lung cancer]. | 2015 | 2 |
| 15 | Virtual cases in internal medicine education | 2015 | 3 |
| 16 | 2014 | 38 | |
| 17 | 2012 | 2 | |
| 18 | [Predictive diagnosis of breast cancer]. | 2011 | 1 |
| 19 | 2007 | 4 | |
| 20 | 2006 | 19 |
About Aleš Ryška
Aleš Ryška is a scholar working on Oncology, Cancer Research, Endocrinology, Diabetes and Metabolism, Dermatology and Pulmonary and Respiratory Medicine, having authored 189 papers that have together received 3.6k indexed citations. Recurring topics across this work include Thyroid Cancer Diagnosis and Treatment (30 papers), Salivary Gland Tumors Diagnosis and Treatment (22 papers), Cancer Genomics and Diagnostics (21 papers), Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (15 papers), Cancer and Skin Lesions (14 papers), Neuroendocrine Tumor Research Advances (13 papers) and Breast Cancer Treatment Studies (11 papers). The work is most often cited by research in Oncology (1.8k citations), Oral Surgery (384 citations), Otorhinolaryngology (197 citations), Cancer Research (628 citations) and Dermatology (288 citations). Aleš Ryška has collaborated with scholars based in Czechia, Italy and United Kingdom. Frequent co-authors include Ján Laco, Alena Skálová, Ilmo Leivo, Cáp J, Tomáš Vaněček, Ivo Stárek, Michal Michal, Zdeněk Kinkor, Bayardo Perez‐Ordoñez and Marie Geierová. Their work appears in journals such as Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin, Histopathology, Cytopathology, Journal for ImmunoTherapy of Cancer and Acta Oto-Laryngologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.